Ipilimumab - Wikipedia
Ipilimumab (trade name Yervoy) is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. ... Read Article
VISN 22 Drug Monograph Template
Natalizumab (Tysabri®) December 2007. VHA Pharmacy Benefits Management Services and the Medical Advisory Panel. Executive Summary: Natalizumab is a monoclonal antibody that is thought to act by inhibiting the migration of leukocytes into the CNS, which in theory leads to a reduction of inflammation and demyelination. ... View Full Source
HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BONIVA Injection safely and effectively. ... Doc Retrieval
HIGHLIGHTS OF PRESCRIBING INFORMATION Observe Patients During ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TYSABRI safely and effectively. See full prescribing information for TYSABRI. TYSABRI (natalizumab) injection, for intravenous use . ... Fetch Document
Tysabri® (natalizumab) - Moda Health
Natalizumab treatment, especially beyond 2 years Elevated levels of anti-JCV antibody response index (i.e., index > 0.9)* *In those using natalizumab for 25–36 months with no prior use of immunosuppressants, the PML risk is 0.2 per 1,000 in those with an index of 0.9 or less, 0.3 per 1,000 in those with an index of 0.9– ... Access Full Source
HIGHLIGHTS OF PRESCRIBING INFORMATION With A Fluoropyrimidine ...
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Melanoma KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma [see Clinical Studies (14.1)]. 1.2 Non-Small Cell Lung Cancer ... Fetch Content
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - Tecfidera
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECFIDERA safely and effectively. See full prescribing information for and had not previously been treated with natalizumab, which has a known association with PML. ... Read Full Source
TYSABRI (natalizumab) COVERAGE AND REIMBURSEMENT
TYSABRI® (natalizumab) COVERAGE AND REIMBURSEMENT - 2 - DECISIE ACTION MATTERS Please see full Prescribing Information, including Boxed Warning, as well as Important Safety Information about TYSABRI on pages 66-70. ... Read Full Source
Payment Policy | Natalizumab (Tysabri®) For Multiple ...
Approximately 10% of patients receiving natalizumab will develop anti-natalizumab antibodies; 6% of patients will experience persistent antibody positivity. A sustained anti-natalizumab antibody level is associated with a substantial decrease in the effectiveness of natalizumab. Anti-natalizumab antibodies usually develop by week 12 of treatment. ... Document Retrieval
Boxed Warning - Wikipedia
In the United States, a boxed warning (sometimes "black box warning", colloquially) is a type of warning that appears on the package insert for certain prescription drugs, so called because the U.S. Food and Drug Administration specifies that it is formatted with a 'box' or border around the text. ... Read Article
HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
1 . HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for ... Document Retrieval
Asparaginase Erwinia Chrysanthemi ERWINAZE - HemOnc.org
ERWINAZE (asparaginase Erwinia chrysanthemi) is an asparagine-specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli- ... Get Content Here
TYSABRI (natalizumab) - Caremark
TYSABRI (natalizumab) Tysabri FEP Clinical Rationale Summary Tysabri is used to prevent episodes of symptoms and slow the worsening of disability in patients with relapsing forms of multiple sclerosis. Tysabri is also used to treat and prevent episodes of symptoms ... Access Doc
HIGHLIGHTS OF PRESCRIBING INFORMATION Conduct Laboratory ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZINBRYTA™ safely and effectively. See full prescribing information for ... Fetch Document
Entyvio VMB245 R2 FULL PRESCRIBING INFORMATION CLEAN 08feb2018
2. Insert the syringe needle into the vial through the center of the stopper and direct the stream of Sterile Water for Injection to the glass wall of the vial to avoid excessive foaming. 3. Gently swirl the vial for at least 15 seconds to dissolve the lyophilized powder. Do not vigorously shake or invert. 4. ... Content Retrieval
Tysabri (natalizumab) Injection Label
TYSABRI(R (natalizumab) Injection . FULL PRESCRIBING INFORMATION . WARG: PROGRESSIV MUTIFOCAL LEUKOENCEPHAOPATH. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an . opportunistic viral infection of . the brain that usually leads to death or severe disabilty. ... View Doc
Emapalumab - Wikipedia
Emapalumab, marketed under the trade name Gamifant, is an anti-interferon-gamma (IFNγ) antibody used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which currently has no cure. ... Read Article
Natalizumab (Tysabri®) For Multiple Sclerosis And Crohn's Disease
Natalizumab is a covered infusion therapy drug only available through the CD-TOUCH prescribing program, for relapsing forms of multiple sclerosis and for moderate-to-severe Crohn's disease. Coverage: ... Read Here
DOSAGE AND ADMINISTRATION -------------------
TYSABRI (natalizumab) injection, for intravenous use Initial U.S. Approval: 2004 WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning • TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain ... Access Full Source
No comments:
Post a Comment